×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:MDGL

Madrigal Pharmaceuticals Price Target, Predictions & Analyst Ratings

$78.55
+4.96 (+6.74%)
(As of 07/5/2022 04:00 PM ET)
Add
Compare
Today's Range
$72.17
$78.86
50-Day Range
$58.04
$84.65
52-Week Range
$52.33
$105.93
Volume
205,005 shs
Average Volume
184,343 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$167.43

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$167.43
113.15% Upside
High Prediction$220.00
Average Prediction$167.43
Low Prediction$111.00
TypeCurrent
7/5/21 to 7/5/22
1 Month Ago
6/5/21 to 6/5/22
3 Months Ago
4/6/21 to 4/6/22
1 Year Ago
7/5/20 to 7/5/21
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$167.43$167.43$170.20$165.63
Predicted Upside113.15% Upside115.31% Upside103.94% Upside37.83% Upside
Get Madrigal Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.


MDGL Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDGL Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Madrigal Pharmaceuticals Stock vs. The Competition

TypeMadrigal PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyBuyBuy
Predicted Upside114.82% Upside473.46% Upside35.11% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
421
71.60%
Underperform Votes
167
28.40%
Avg. Outperform Votes
166
66.94%
Avg. Underperform Votes
82
33.06%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical Madrigal Pharmaceuticals Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/12/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Nash
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$133.00 ➝ $151.00+143.55%
5/10/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$180.00 ➝ $170.00+192.90%
2/7/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jonathan Wolleben
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$220.00+192.05%
11/7/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$199.00+113.89%
10/6/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$151.00+92.72%
8/11/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ed Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$184.00 ➝ $170.00+101.35%
8/6/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
6/28/2021B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Mamtani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/4/2021Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$202.00 ➝ $203.00+81.06%
11/6/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$118.00 ➝ $126.00+1.33%
11/5/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$208.00 ➝ $204.00+52.13%
8/6/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Derek Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$114.00+7.12%
3/5/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$166.00 ➝ $155.00+71.03%
2/27/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
1/9/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$125.00 ➝ $127.00+46.57%
1/2/2020SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/5/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Madrigal Pharmaceuticals Price Target - Frequently Asked Questions

What is Madrigal Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Madrigal Pharmaceuticals stock is Buy based on the current 6 buy ratings for MDGL. The average twelve-month price prediction for Madrigal Pharmaceuticals is $167.43 with a high price target of $220.00 and a low price target of $111.00. Learn more on MDGL's analyst rating history.

Do Wall Street analysts like Madrigal Pharmaceuticals more than its competitors?

Analysts like Madrigal Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for Madrigal Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how MDGL compares to other companies.

Do MarketBeat users like Madrigal Pharmaceuticals more than its competitors?

MarketBeat users like Madrigal Pharmaceuticals stock more than the stock of other Medical companies. 71.60% of MarketBeat users gave Madrigal Pharmaceuticals an outperform vote while medical companies recieve an average of 67.07% outperform votes by MarketBeat users.

Does Madrigal Pharmaceuticals's stock price have much upside?

According to analysts, Madrigal Pharmaceuticals's stock has a predicted upside of 115.31% based on their 12-month price targets.

What analysts cover Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has been rated by Canaccord Genuity Group, and Oppenheimer in the past 90 days.

This page (NASDAQ:MDGL) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.